The IsCHEMiA score, an imaging-based risk model validated across international cohorts, offers superior prediction of poststroke epilepsy compared to previous tools. By integrating clinical and neuroimaging markers, it provides a precise framework for personalized management and the design of future antiepileptogenic clinical trials.